O,S-diethyl-dithiophosphoric acid | 60899-79-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机二硫代磷酸及其衍生物
• 英文名称: O,S-diethyl-dithiophosphoric acid
• 英文别名: diethyl dithiophosphate；dithiophosphoric acid O,S-diethyl ester；Dithiophosphorsaeure-O,S-diaethylester；Dithiophosphoric acid diethyl ester；ethoxy-ethylsulfanyl-hydroxy-sulfanylidene-λ5-phosphane
• CAS: 60899-79-8
• 化学式: C₄H₁₁O₂PS₂
• 分子量: 186.236
• InChiKey: OILHDBLLQZLFFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  86.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  O,S-diethyl-dithiophosphoric acid 、 (alphaS,betaR)-beta-(2,4-二氟苯基)-beta-羟基-alpha-甲基-1H-1,2,4-三唑-1-丁腈 以 水 、 异丙醇 为溶剂， 反应 9.0h， 以97%的产率得到(alphaR,betaR)-beta-(2,4-二氟苯基)-beta-羟基-alpha-甲基-1H-1,2,4-三唑-1-丁烷硫代酰胺
  参考文献：
  名称：

  三唑类抗真菌剂关键中间体的对映选择性合成；Efinaconazole（Jublia）在催化不对称合成中的应用

  摘要：

  开发了一种新的合成路线，该路线是迄今为止报道的最短路线，可通往合成各种三唑抗真菌剂的关键中间体。通过高级酮的催化不对称氰基硅烷化反应构建了在高级三唑抗真菌剂中必不可少的难以捉摸的四取代立体异构中心。随后的转化以两个一锅操作进行，从而提高了中间体的整体合成效率。这种简化的合成方法已成功地应用于依非那康唑（Jublia）和拉伏康唑的有效对映选择性合成。

  DOI：

  10.1021/jo500369y
• 作为试剂：
  描述：

  (alphaS,betaR)-beta-(2,4-二氟苯基)-beta-羟基-alpha-甲基-1H-1,2,4-三唑-1-丁腈 在 O,S-diethyl-dithiophosphoric acid 、 硫酸 、 potassium carbonate 、 三乙胺 、 碘甲烷 作用下， 以 乙醇 、 水 、 异丙醇 、 丙酮 为溶剂， 反应 25.5h， 生成 (2R,3R)-2-(2,4-difluorophenyl)-3-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-1,3-thiazol-2-yl]-1-(1,2,4-triazol-1-yl)butan-2-ol
  参考文献：
  名称：

  Synthesis and Antifungal Activity of Novel Thiazole-Containing Triazole Antifungals. II. Optically Active ER-30346 and Its Derivatives.

  摘要：

  一系列含有噻唑结构的三唑类抗真菌药物被合成并评估了它们对临床分离的各种致病真菌的体外抗真菌活性以及对体内系统性念珠菌病的疗效。这些化合物在体内外均显示出强大的抗真菌活性。特别是，(2R, 3R)-3-[4-(4-氰基苯基)噻唑-2-基]-2-(2, 4-二氟苯基)-1-(1H-1, 2, 4-三唑-1-基)-2-丁醇（12g；ER-30346）显示出强大的且平衡良好的体外活性以及强效的体内疗效，并且具有良好的安全性特征。

  DOI：

  10.1248/cpb.46.623

文献信息

• Phthalazine derivatives and remedies for erectile dysfunction
  申请人：Eisai Co., Ltd.

  公开号：US06498159B1

  公开（公告）日：2002-12-24

  The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: wherein R1 and R2 are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R1 is a chlorine atom, R2 is a methoxy group and Y is a 5- or 6-membered amine ring substituted with a hydroxyl group is excluded.

  本发明提供了一种邻苯二氮杂环化合物，作为下式所代表的勃起功能障碍的治疗剂，其药理学上可接受的盐或水合物： 其中R1和R2相同或不同，分别代表卤素原子、可能被卤素原子取代的C1到C4烷基、可能被卤素原子取代的C1到C4烷氧基或氰基；X代表氰基、硝基、卤素原子、可能被取代的羟基亚胺基团或可能被取代的杂芳基团；Y代表杂芳基团、可能被取代的芳基团、可能被取代的炔基团、烯基团、烷基团、可选择地取代的饱和或不饱和的4-至8-成员氨基环，且环状胺化合物是单环化合物、双环化合物或螺环化合物；l为1到3的整数；但在l为1或2的情况下，X为氰基、硝基或氯原子，R1为氯原子，R2为甲氧基团，Y为取代羟基的5-或6-成员氨基环的情况除外。
• Tricyclic compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06248766B1

  公开（公告）日：2001-06-19

  A compound of the formula: wherein R1 is H or a substituent; m is 1-3; Ar is an aromatic group which may be substituted; X is a bond or a divalent straight-chain group having 1-6 atoms which may be substituted; Y is —S—, —O—, or —N(R2— (R2 is H or a substituent group), Z is —N═ or —C(R3)═ (R3 is H or a hydrocarbon group), ring A is a benzene ring; ring B is a 5- to 7-membered ring which may be substituted, or a salt thereof is useful for eliciting a prostaglandin I2 receptor agonistic effect.

  该公式的化合物： 其中R1为H或取代基；m为1-3；Ar为可能被取代的芳香基团；X为键或具有1-6个原子的二价直链基团，可能被取代；Y为—S—，—O—或—N(R2— (R2为H或取代基团)，Z为—N═或—C(R3)═ (R3为H或碳氢基团)，环A为苯环；环B为可能被取代的5-至7-成员环，或其盐对诱导前列腺素I2受体激动效应有用。
• Therapeutically Active Fused Pyrimidine Derivatives
  申请人：Brookings Daniel Christopher

  公开号：US20140309222A1

  公开（公告）日：2014-10-16

  A series of monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

  一系列单环或双环二胺取代的噻吩[2,3-d]嘧啶和异噻唑[5,4-d]嘧啶衍生物在治疗和/或预防各种人类疾病方面具有益处，包括炎症性、自身免疫和肿瘤性疾病；病毒性疾病；以及器官和细胞移植排斥。
• N-(4- carbamimidoyl-phenyl) -glycine derivatives
  申请人：——

  公开号：US20010001799A1

  公开（公告）日：2001-05-24

  The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula: 1 wherein R 1 , E, X 1 to X 4 and G 1 and G 2 are as defined in the description and the claims, as well as hydrates or solvates and physiologically usable salts thereof.

  这项发明涉及一种新颖的公式为N-(4-羰基苄基)-甘氨酸衍生物，其中R1、E、X1至X4以及G1和G2如描述和权利要求中所定义，以及其水合物或溶剂合物和生理可用盐。
• Process for preparing cyano derivatives of tetrahydroquinolines and
  申请人：John Wyeth & Brother Limited

  公开号：US04529798A1

  公开（公告）日：1985-07-16

  Fused carbocyclic ring derivatives of pyridine which contain a nitrile or thioamide group on the carbocyclic ring e.g. 8-cyano or thiocarboxamido-5,6,7,8-tetrahydroquinolines are prepared by a process in which a sodium, potassium, lithium or magnesium halide derivative of the pyridine compound is treated with a compound RaRbNCN wherein Ra and Rb are the same or different and represent alkyl, cycloalkyl, or aralkyl, or Ra and Rb are joined to form a heterocyclic ring with the nitrogen, and the product is treated with a proton source to obtain the nitrile which is optionally treated with a sulphurizing agent to form the thioamide. The nitriles or thioamides may be isolated as their acid addition salts.

  含有腈基或硫代酰胺基团的吡啶融合碳环衍生物，例如8-氰基或硫代羧酰胺基-5,6,7,8-四氢喹啉，可通过以下过程制备：用含有钠、钾、锂或镁卤化物衍生物的吡啶化合物处理化合物RaRbNCN，其中Ra和Rb相同或不同，代表烷基、环烷基或芳基，或Ra和Rb连接形成与氮原子相连的杂环环，然后用质子源处理产物以获得腈基，可选择用硫化剂处理腈基以形成硫代酰胺基团。腈基或硫代酰胺基团可作为其酸盐分离。